



(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 39/00 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2021/035542

(22) International Filing Date:

02 June 2021 (02.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/033,755	02 June 2020 (02.06.2020)	US
63/058,359	29 July 2020 (29.07.2020)	US
63/084,474	28 September 2020 (28.09.2020)	US

(71) Applicant: **DYNAMICURE BIOTECHNOLOGY LLC**
[US/US]; One Broadway 14FL, Cambridge, Massachusetts
02142 (US).

(72) Inventors: **CHEN, Zirong**; c/o DYNAMICURE
BIOTECHNOLOGY LLC, One Broadway 14FL, Cam-
bridge, Massachusetts 02142 (US). **GUERRETTE, Rox-**


ann; c/o DYNAMICURE BIOTECHNOLOGY LLC, One
Broadway 14FL, Cambridge, Massachusetts 02142 (US).
JONES, Gregory; c/o DYNAMICURE BIOTECHNOLO-
GY LLC, One Broadway 14FL, Cambridge, Massachusetts
02142 (US). **KOMABA, Shigeru**; c/o DYNAMICURE
BIOTECHNOLOGY LLC, One Broadway 14FL, Cam-
bridge, Massachusetts 02142 (US). **LI, Jian**; c/o DY-
NAMICURE BIOTECHNOLOGY LLC, One Broadway
14FL, Cambridge, Massachusetts 02142 (US). **NORTON,**
Angela; c/o DYNAMICURE BIOTECHNOLOGY LLC,
One Broadway 14FL, Cambridge, Massachusetts 02142
(US). **WU, Lihua**; c/o DYNAMICURE BIOTECHNOL-
OGY LLC, One Broadway 14FL, Cambridge, Massa-
chusetts 02142 (US). **XIA, Zhinan**; c/o DYNAMICURE
BIOTECHNOLOGY LLC, One Broadway 14FL, Cam-
bridge, Massachusetts 02142 (US).

(74) Agent: **YOU, Yuying** et al.; Morrison & Foerster LLP, 755
Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

(54) Title: ANTI-CD93 CONSTRUCTS AND USES THEREOF

FIG. 15A



(57) Abstract: The present application provides anti-CD93 constructs that bind to CD93 (*e.g.*, anti-CD93 antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-CD93, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-CD93 construct, pharmaceutical compositions containing the anti-CD93 construct, and methods of using the anti-CD93 construct or compositions.

[Continued on next page]

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*